CRMDHealthcare · BiotechnologyThe 6 Wall Street analysts covering CorMedix, Inc. hold a median 12-month price target of $15 — +165.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 3 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores CorMedix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CRMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +165.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Oct 2026 | Needham | Reiterates | Buy | $15 |
| 23 Sept 2026 | Oppenheimer | Initiates | Outperform | $15 |
| 23 Sept 2026 | Oppenheimer | Initiates | Outperform | — |
| 14 Aug 2026 | RBC Capital | Maintains | Outperform | $13 → $14 |
| 14 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 7 July 2026 | RBC Capital | Maintains | Outperform | $14 → $13 |
| 7 July 2026 | RBC Capital | Maintains | Outperform | — |
| 28 Apr 2026 | Citizens | Reiterates | Market Outperform | — |
| 28 Apr 2026 | Leerink Partners | Maintains | Outperform | — |
| 28 Apr 2026 | RBC Capital | Maintains | Outperform | — |
| 27 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 27 Apr 2026 | Needham | Maintains | Buy | — |
| 5 Mar 2026 | Needham | Maintains | Buy | — |
| 11 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 23 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 21 Jan 2026 | RBC Capital | Maintains | Outperform | — |
| 8 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Jan 2026 | Needham | Maintains | Buy | — |
| 18 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 13 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CRMD appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, CorMedix, Inc. returned −50.4% against +12.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 68% of US stocks
Cheaper than 70% of US stocks
Cheaper than 73% of US stocks
Cheaper than 58% of US stocks
Higher than 95% of US stocks
Higher than 67% of US stocks
Higher than 87% of US stocks
Higher than 93% of US stocks
Higher than 94% of US stocks
Higher than 94% of US stocks
Higher than 99% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CorMedix, Inc. has a market value of $420.1M and an enterprise value of $310.9M.
Revenue in the twelve months to 30 June 2026: $459.6M. The latest quarter grew 156.5% year on year.
Net income over the same four quarters: $187.2M, a 40.7% net margin.
Diluted earnings per share, trailing twelve months: $2.14.
Free cash flow in the twelve months to 30 June 2026: $250.4M.
Trailing P/E: 2.6×; forward P/E: 15.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
CorMedix, Inc. employs 191 people — $2.4M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CorMedix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research previewed CorMedix’s upcoming Q3 earnings report, saying the company lacks the combination of two key ingredients associated with a likely earnings beat.
Why it matters — The preview signals that expectations for a Q3 earnings beat are limited, a point CRMD watchers may consider ahead of the report.
CorMedix Therapeutics provided a business update ahead of a November 12, 2026 conference call to discuss its complete quarterly financial performance. The headline says the company reaffirmed 2026 total revenue guidance and reported its third-quarter cash position.
Why it matters — The update gives CRMD watchers a preview of the topics the company plans to address before the full quarterly results discussion.
The FDA accepted for filing Mundipharma’s sNDA for REZZAYO (rezafungin) to prevent invasive fungal disease and granted it Priority Review, with a PDUFA target action date in Q1 2027. The application is supported by the Phase III ReSPECT study; CorMedix said it is targeting promotional efforts in H2 2027 if the indication is approved.
Why it matters — The review advances a potential new REZZAYO indication and establishes an FDA decision timeline relevant to CorMedix’s development and commercial plans.
Actinium Pharmaceuticals announced that Matt David, M.D., has been appointed Chief Financial Officer.
Why it matters — The announcement concerns Actinium Pharmaceuticals, not CorMedix, and provides no company-specific information about CRMD.
Zacks Investment Research compares CorMedix (CRMD) and Prothena (PRTA) for investors interested in Medical - Biomedical and Genetics stocks, asking which offers better value.
Why it matters — The item frames CRMD in a comparison focused on value investing alongside Prothena.
The 6 Wall Street analysts covering CorMedix, Inc. have a median 12-month price target of $15, with estimates ranging from $13 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering CorMedix, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CorMedix, Inc. 62 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, CorMedix, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +165.0% from the last close, and Ticker Nerd's factor model ranks CorMedix, Inc. 62 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CorMedix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $19 over the next 12 months.
CorMedix, Inc. returned -50.4% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.
The most recent item we track (Zacks Investment Research, 4 Nov 2026): "Earnings Preview: CorMedix (CRMD) Q3 Earnings Expected to Decline". Zacks Investment Research previewed CorMedix’s upcoming Q3 earnings report, saying the company lacks the combination of two key ingredients associated with a likely earnings beat.
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Its current commercial focus centers on DefenCath, an antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through central venous catheters. The company serves healthcare providers and dialysis settings, where preventing bloodstream infections is a critical part of patient care. CorMedix also operates as a specialty pharmaceutical business with a product portfolio aimed at acute care markets and other medically important settings. Headquartered in Berkeley Heights, New Jersey, CorMedix Inc. plays a targeted role in the healthcare market by addressing complications associated with vascular access and chronic kidney failure treatment.
CEO Mr. Joseph Todisco MBA · 191 employees · United States · https://cormedix.com
